• Profile
Close

Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: A network meta-analysis

Osteoporosis International Apr 12, 2019

Reginster JY, et al. - In this network meta-analysis (NMA), researchers estimated the relative effectiveness of abaloparatide vs other therapies to reduce the risk of fractures in women with postmenopausal osteoporosis (PMO). In all, abaloparatide exhibited the greatest treatment effect relative to placebo in the vertebral fracture (VF) network, the nonvertebral (NVF) network, and the wrist fracture network vs other treatments. Compared with other treatments, abaloparatide had the greatest estimated possibility to prevent the fractures in the following networks: 79% for VF, 70% for NVF, and 53% for wrist fracture.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay